Italia markets closed
FTSE MIB
33.922,16 +40,66 (+0,12%) Dow Jones
37.986,40 +211,02 (+0,56%) Nasdaq
15.282,01 -319,49 (-2,05%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
83,24 +0,51 (+0,62%) Bitcoin EUR
59.633,04 -53,56 (-0,09%)
Johnson & Johnson (0R34.IL)
IOB - IOB Prezzo differito. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 07:14PM BST
| Chiusura precedente | 144,90 |
| Aperto | 144,69 |
| Denaro | 142,40 x N/D |
| Lettera | 150,20 x N/D |
| Min-Max giorno | 143,59 - 147,24 |
| Intervallo di 52 settimane | 143,14 - 175,85 |
| Volume | |
| Media Volume | 161.949 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | 17 lug 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireAlvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA
© 2024 Yahoo. Tutti i diritti riservati.